Evotec AG (NASDAQ:EVO) Receives Consensus Rating of “Hold” from Brokerages

Evotec AG (NASDAQ:EVO) has been assigned an average rating of “Hold” from the five research firms that are covering the firm, MarketBeat reports. One analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating on the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $3.00.

Several research analysts have weighed in on the company. TD Cowen downgraded Evotec from a “buy” rating to a “hold” rating and set a $2.00 price target for the company. in a research note on Wednesday, July 15th. Weiss Ratings cut shares of Evotec from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, August 25th. HC Wainwright lowered their target price on shares of Evotec from $7.00 to $4.00 and set a “buy” rating on the stock in a report on Wednesday, July 15th. Berenberg Bank lowered shares of Evotec from a “buy” rating to a “hold” rating in a research report on Thursday, July 16th. Finally, Wall Street Zen downgraded shares of Evotec from a “hold” rating to a “sell” rating in a report on Saturday, May 9th.

Evotec Stock Performance

NASDAQ:EVO opened at $1.80 on Wednesday. The stock has a 50-day moving average price of $2.20 and a 200 day moving average price of $2.65. Evotec has a 12-month low of $1.80 and a 12-month high of $4.27. The company has a current ratio of 2.33, a quick ratio of 2.21 and a debt-to-equity ratio of 0.62.

Institutional Investors Weigh In On Evotec

Large investors have recently made changes to their positions in the company. Apollon Wealth Management LLC purchased a new stake in shares of Evotec in the first quarter worth about $28,000. BNP Paribas Financial Markets grew its holdings in Evotec by 62.2% during the 2nd quarter. BNP Paribas Financial Markets now owns 12,000 shares of the company’s stock valued at $50,000 after buying an additional 4,600 shares in the last quarter. Bank of America Corp DE grew its holdings in Evotec by 262.5% during the 4th quarter. Bank of America Corp DE now owns 12,828 shares of the company’s stock valued at $53,000 after buying an additional 9,289 shares in the last quarter. Marshall Wace LLP bought a new stake in Evotec in the 4th quarter worth approximately $40,000. Finally, XTX Topco Ltd bought a new stake in Evotec in the 2nd quarter worth approximately $66,000. 5.81% of the stock is owned by institutional investors.

Evotec Company Profile

Evotec SE (NASDAQ:EVO) is a global biotechnology company headquartered in Hamburg, Germany, specializing in drug discovery and development partnerships. The company leverages its integrated discovery platforms to support pharmaceutical and biotech clients in advancing novel therapies from target identification through preclinical development.

Evotec’s service offering encompasses high-throughput screening, bioanalytics, combinatorial chemistry, structural biology, pharmacology, and computational drug design.